Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N0728
- Development stage
- Phase 4
- Lead developer
- Eurofarma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**N0728** is Eurofarma's oral fixed-dose combination of solifenacin and tamsulosin under Phase 3 evaluation for moderate-to-severe lower urinary tract symptoms associated with benign prostatic hyperplasia. Solifenacin is an antimuscarinic agent that reduces detrusor overactivity and storage symptoms, while tamsulosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow and voiding symptoms. The BENIPRO trial is evaluating N0728 against the established solifenacin/tamsulosin product Vesomni. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06546735))
- Other names
- solifenacin + tamsulosin
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)
Beyond the preview
Go deeper on N0728.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N0728.